Biotechnology Today
more-
PharmaLegacy acquires BTS Research in hopes of becoming a ‘highly competitive global CRO’
PharmaLegacy Laboratories is snapping up BTS Research in hopes of expanding its reach as a…
Exact Sciences shows off early colorectal cancer blood test data
Lantheus’ phase 3 radiotherapy readout not enough to topple Pluvicto, say analysts
Boehringer’s phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Jazz HER2 bispecific posts 59% survival at 30 months in gastric cancer
Markets
more-
Weekly Market Review – December 21, 2024
Stock Markets All major indexes moved sharply lower when it was determined that only two…
Bio Space
more
Kairos goes public with $6M IPO to fund trials of lead cancer drug
With a trio of biotechs hitting the Nasdaq on Friday,…
Amgen and Merck become first industry partners of academic clinical trial diversity initiative
An academic partnership to improve diversity in clinical trials has…
Novo Nordisk’s latest RNA deal involves $530M biobucks to sing in Korro’s opera
Novo Nordisk isn’t done with the RNA deals, this time…
Global News
more
SpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
Facebook video calls soar 1000% during Italy’s lockdown
Facebook has seen usage across its platforms surge in countries…
WeWork board’s special committee is demanding that SoftBank follow through with investment
Five months after SoftBank agreed to a massive bailout of…
PharmaLegacy acquires BTS Research in hopes of becoming a ‘highly competitive global CRO’
Exact Sciences shows off early colorectal cancer blood test data
Lantheus’ phase 3 radiotherapy readout not enough to topple Pluvicto, say analysts
Boehringer’s phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Kairos goes public with $6M IPO to fund trials of lead cancer drug
Amgen and Merck become first industry partners of academic clinical trial diversity initiative
Novo Nordisk’s latest RNA deal involves $530M biobucks to sing in Korro’s opera
Bristol Myers axes Immatics’ bispecific after $150M bet
Jazz HER2 bispecific posts 59% survival at 30 months in gastric cancer
Pfizer sees weight gain in cancer patients, aims to enter phase 3 in 2025